Branched Antisense and siRNA Co-Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy

Angew Chem Int Ed Engl. 2021 Jan 25;60(4):1853-1860. doi: 10.1002/anie.202011174. Epub 2020 Nov 24.

Abstract

Chemically modified DNA has been widely developed to fabricate various nucleic acid nanostructures for biomedical applications. Herein, we report a facile strategy for construction of branched antisense DNA and small interfering RNA (siRNA) co-assembled nanoplatform for combined gene silencing in vitro and in vivo. In our design, the branched antisense can efficiently capture siRNA with 3' overhangs through DNA-RNA hybridization. After being equipped with an active targeting group and an endosomal escape peptide by host-guest interaction, the tailored nucleic acid nanostructure functions efficiently as both delivery carrier and therapeutic cargo, which is released by endogenous RNase H digestion. The multifunctional nucleic acid nanosystem elicits an efficient inhibition of tumor growth based on the combined gene silencing of the tumor-associated gene polo-like kinase 1 (PLK1). This biocompatible nucleic acid nanoplatform presents a new strategy for the development of gene therapy.

Keywords: cancer therapy; drug delivery; gene therapy; nucleic acid nanostructure; self-assembly.

MeSH terms

  • Animals
  • Gene Silencing*
  • Genetic Therapy*
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Nanoparticles / chemistry*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Proof of Concept Study
  • RNA Interference
  • RNA, Antisense / chemistry*
  • RNA, Small Interfering / chemistry*

Substances

  • RNA, Antisense
  • RNA, Small Interfering